Efficacy News and Research

RSS

FDA's ODAC to review CTI's pixantrone NDA on March 22, 2010

Cell Therapeutics, Inc. announced today that the U.S. Food and Drug Administration's ("FDA") Oncologic Drugs Advisory Committee ("ODAC") will review CTI's New Drug Application ("NDA") for pixantrone for the treatment of relapsed/refractory aggressive non-Hodgkin's lymphoma ("NHL") on March 22, 2010.

2 Mar 2010

Scopolamine drug: A rapid-acting antidepressant for depression symptoms

Conventional antidepressant treatments generally require three to four weeks to become effective, thus the discovery of treatments with a more rapid onset is a major goal of biological psychiatry. The first drug found to produce rapid improvement in mood was the NMDA glutamate receptor antagonist, ketamine.

1 Mar 2010

ChemGenex Pharmaceuticals' OMAPRO review: FDA reschedules ODAC meeting to 22 March, 2010

ChemGenex Pharmaceuticals Limited announced today that the U.S. Food and Drug Administration (FDA) has rescheduled the previously postponed Oncologic Drugs Advisory Committee (ODAC) meeting to 22 March 2010.

1 Mar 2010

Uroplasty's Urgent PC Neuromodulation System SUmiT Trial demonstrates effectiveness of PTNS

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today highlighted results of the SUmiT Trial of its Urgent® PC Neuromodulation System that will be published in the April 2010 print edition of THE JOURNAL OF UROLOGY® and is now available on line.

1 Mar 2010

Oral immunotherapy promising for egg allergies, SLIT for milk allergies

Children with egg allergies who consume increasingly higher doses of egg protein - the very nutrient they react to - appear to gradually overcome their allergies, tolerating eggs better over time and with milder symptoms, according to research conducted at Johns Hopkins Children's Center and elsewhere.

1 Mar 2010

arGEN-X SIMPLE Antibody platform delivers multiple, diverse, ultra-potent functional antibodies

SIMPLE Antibody(TM) Platform Delivers Unprecedented Choice of Ultra-Potent Functional Antibody Leads Against Challenging Soluble and Cell Surface Targets. - ARGX-109, a Fully Human mAb Targeting Autoimmune, Inflammation and Oncology Indications, Enters Preclinical Development in Less Than 12 Months From Start of Discovery.

1 Mar 2010

Two stroke-prevention procedures are equally beneficial for men and women, but effectiveness vary by age

Two stroke-prevention procedures are safe and equally beneficial for men and women at risk for stroke, but the effectiveness does vary by age, say researchers at the University of Alabama at Birmingham in collaboration with other North American stroke investigators.

1 Mar 2010

Using genetic engineering techniques in pigs, scientists create new model of diabetes

The incidence of diabetes is rising worldwide. Using genetic engineering techniques in pigs, scientists at Ludwig-Maximilians-Universität in Munich have created a new model of this metabolic disorder, which recapitulates many features of the disease, and promises to contribute significantly to improvements in diagnosis and therapy.

1 Mar 2010

Diagosis of head and neck lesions: Ultrasound-guided FNA better than standard palpation technique

Office-based, surgeon-performed, ultrasound-guided, fine needle aspiration (FNA) of head and neck lesions yields a statistically significant higher diagnostic rate compared to the standard palpation technique, indicates new research in the March 2010 issue of Otolaryngology - Head and Neck Surgery.

1 Mar 2010

NPS Pharmaceuticals supports second annual U.S. Rare Disease Day observance

NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, announced today its support for the second annual U.S. Rare Disease Day observance on February 28.

1 Mar 2010

Study shows ghrelin prevents acute liver damage, reduces oxidative stress and inflammation

Spanish researchers determined that rats treated with recombinant ghrelin displayed a reduction in liver fibrosis. Ghrelin, a stomach hormone, reduced the amount of fibrogenic cells by 25% in the treated rodents. Research further showed ghrelin prevented acute liver damage and reduced oxidative stress and inflammation in the animal models.

1 Mar 2010

FiberNet EPS has 97.5% success rate in patients undergoing CAS: EPIC study

A multicenter EPIC (FiberNet- Embolic Protection System in Carotid Artery Stenting Trial) study found that the FiberNet Embolic Protection System (EPS) had a 97.5% success rate when used in patients undergoing carotid artery stenting (CAS). Full findings are published early online in Catheterization and Cardiovascular Interventions, the official journal of The Society for Cardiovascular Angiography and Interventions.

1 Mar 2010

ADMET tester Absorption Systems joins Society of Toxicology as Affiliate

Absorption Systems, a leader in testing drugs for ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity), has joined the Society of Toxicology, the premier global professional association of toxicologists, as an SOT Affiliate. The firm, a contract research organization, has more than a decade of experience assisting pharmaceutical and biotechnology companies in determining which compounds in development should be advanced into clinical testing.

27 Feb 2010

Eli Lilly, Covance announce key milestones of their first-year partnership

Senior executives from Eli Lilly and Company and Covance Inc. announced Friday that the first year of their landmark alliance has been a win-win for both companies, enabling Lilly to expedite the flow of innovation within its pipeline in order to provide improved outcomes for individual patients.

27 Feb 2010

Minimally-invasive procedure as effective as gold standard for treating carotid artery blockages: Study

A major study shows that a minimally-invasive procedure is as effective and safe as the gold standard for treating blockages of the carotid artery, giving patients who prefer a less invasive procedure a proven alternative.

27 Feb 2010

Overall incidence of stroke, heart attack and death similar in carotid endarterectomy and stenting procedures

The two major procedures for opening blocked neck arteries to restore blood flow to the brain proved similar in overall long-term safety and efficacy, but showed differences in stroke and heart attack in the weeks following the procedure, according to late-breaking science presented at the American Stroke Association's International Stroke Conference 2010.

27 Feb 2010

CREST stroke prevention trial: Seminal and robust

The CREST trial that compared traditional surgery with less-invasive stenting to clear dangerously clogged carotid arteries in the neck is being called "seminal and robust."

27 Feb 2010

Dabigatran as effective as warfarin in preventing subsequent strokes among atrial fibrillation patients

The drug dabigatran was as effective as the currently recommended drug – warfarin – in preventing a subsequent stroke among people with atrial fibrillation and prior stroke or transient ischemic attack – and it did so with less bleeding according to late-breaking science presented at the American Stroke Association's International Stroke Conference 2010.

27 Feb 2010

Carotid artery stenting and carotid endarterectomy equally safe and effective for people at risk for stroke

Carotid artery stenting, a less invasive alternative to surgery on the carotid artery (carotid endarterectomy), is equally safe and effective for people at risk for stroke as carotid endarterectomy, according to a major new study presented today at the 2010 International Stroke Conference in San Antonio, Texas.

26 Feb 2010

Wound Management Technologies announces recent increase in sales of CellerateRx throughout U.S.

Wound Management Technologies, Inc. announced today that the recent increase in sales activities throughout the United States has resulted in 45 new clinicians evaluating their advanced wound care collagen product, CellerateRx® . In the last two months, these evaluations have transpired into new customers in Arizona, New Mexico, South Carolina, North Dakota, New Jersey, Wyoming, Colorado, and New York.

26 Feb 2010

Efficacy News and Research

FDA's ODAC to review CTI's pixantrone NDA on March 22, 2010

Scopolamine drug: A rapid-acting antidepressant for depression symptoms

ChemGenex Pharmaceuticals' OMAPRO review: FDA reschedules ODAC meeting to 22 March, 2010

Uroplasty's Urgent PC Neuromodulation System SUmiT Trial demonstrates effectiveness of PTNS

Oral immunotherapy promising for egg allergies, SLIT for milk allergies

arGEN-X SIMPLE Antibody platform delivers multiple, diverse, ultra-potent functional antibodies

Two stroke-prevention procedures are equally beneficial for men and women, but effectiveness vary by age

Using genetic engineering techniques in pigs, scientists create new model of diabetes

Diagosis of head and neck lesions: Ultrasound-guided FNA better than standard palpation technique

NPS Pharmaceuticals supports second annual U.S. Rare Disease Day observance

Study shows ghrelin prevents acute liver damage, reduces oxidative stress and inflammation

FiberNet EPS has 97.5% success rate in patients undergoing CAS: EPIC study

ADMET tester Absorption Systems joins Society of Toxicology as Affiliate

Eli Lilly, Covance announce key milestones of their first-year partnership

Minimally-invasive procedure as effective as gold standard for treating carotid artery blockages: Study

Overall incidence of stroke, heart attack and death similar in carotid endarterectomy and stenting procedures

CREST stroke prevention trial: Seminal and robust

Dabigatran as effective as warfarin in preventing subsequent strokes among atrial fibrillation patients

Carotid artery stenting and carotid endarterectomy equally safe and effective for people at risk for stroke

Wound Management Technologies announces recent increase in sales of CellerateRx throughout U.S.

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News